Table 1: Various drugs/therapies and their effect on LP(a) reduction [11,36].
|
Drugs/Therapies |
Main Effect |
Reduction effect on LP(a) levels |
|
1. Inclisiran (PCK9i) |
LDL-C reduction |
Minus 20-26% |
|
2. Mipomersen |
Inhibits Apo(b)-100 synthesis |
Minus 26.4% |
|
3. Lomitapide |
Inhibits VLDL synthesis |
Minus 3% |
|
4. Anacetrapib |
Promotes HDL and Inhibits LDL synthesis |
Minus 25% |
|
5. Estrogens |
Promotes HDL and Inhibits LDL synthesis |
Minus 10-15% |
|
6. Niacin |
TG-reduction |
Minus 20% |
|
7. Lipid apheresis therapy |
LP(a) reduction |
Minus 35% |
|
8. ARO-ANG (ANGPTL3i) |
LDL-C and TG reduction |
Unknown |
|
9. Nicotinic acids |
Inhibits LP(a) promoters via AMP |
Minus 20-30% |
|
10. SLN 360 |
Targets LP(a) |
Minus 46-90% |
|
11. ARO-APOC-III (APOC-IIIi) |
TG reduction |
Unknown |
|
12. Olpasiran |
Targets LP(a) |
Minus 80-97% |
|
13. AKCEA-APO(a)-LRx (Pelacarsen) |
Targets LP(a) |
Minus 80% |
PCK9i: Proprotein Convertase Kexin type 9 Inhibitor; ANGPTL3: Angiopoietin-like Protein 3 Inhibitor; APOC-IIIi: Apolipoprotein C-III Inhibitor; VLDL: Very Low-Density Lipoprotein; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; TG: Triglyceride